A promising molecule, called BT13, has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.
Researchers from the University of Helsinki have found that molecule BT13 has the potential to both boost levels of dopamine, the chemical that is lost in Parkinson’s, as well as protecting the dopamine-producing brain cells from dying.
The results from the study, co-funded by Parkinson’s UK, showed an increase in dopamine levels in the brains of mice following treatment with the molecule. BT13 also activated a specific receptor in the mouse brains to protect the cells.
These findings suggest that BT13 could have the potential to lead to a new drug treatment that can slow, stop or even reverse the loss of brain cells in Parkinson’s.
Why is dopamine important?
Typically, by the time people are diagnosed with Parkinson’s, they have already lost 70-80 per cent of their dopamine-producing cells. These are involved in coordinating movement.
Current treatments mask the symptoms, but there is nothing that can slow down its progression or prevent more brain cells from being lost. As dopamine levels continue to fall, symptoms get worse and new symptoms can appear.
The role of BT13
Researchers are now working on improving the properties of BT13 to make it more effective as a potential treatment. If successful, this could benefit the 145,000 people living with Parkinson’s in the UK.
The study builds on previous research on another molecule that targets the same receptors in the brain, glial cell line-derived neurotrophic factor (GDNF), an experimental treatment for Parkinson’s which was the subject of a major clinical trial funded by Parkinson’s UK. While the results were not clear cut, GDNF has shown promise to restore damaged cells in Parkinson’s.
The GDNF protein requires complex surgery to deliver the treatment to the brain because it’s a large molecule. However BT13, a smaller molecule, could be more easily administered as a treatment if shown to be beneficial in further clinical trials.
“The molecule holds great promise”
Professor David Dexter, Deputy Director of Research at Parkinson’s UK, said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms.
“One of the biggest challenges for Parkinson’s research is how to get drugs past the blood-brain barrier, so the exciting discovery of BT13 has opened up a new avenue for research to explore.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- FDA turns down Acadia Pharma drug for Alzheimer’s psychosis; new trial needed
Acadia Pharmaceuticals drug Nuplazid failed to win FDA approval for the treatment of psychosis in Alzheimer’s disease patients. The regulator said that the data submitted were not from an adequate and ...
- Parkinson's research: Experimental nanobody targets toxic proteins
An experimental nanobody treatment that can untangle misshapen proteins in the brain may better address the symptoms of Parkinson's disease.
- Israeli study showing higher Parkinson’s disease risk in PTSD patients bolsters research on US veterans
A new study published Thursday in the Journal of the American Medical Association concluded that there is a “robust” association between PTSD and Parkinson’s risk in men, particularly among elderly ...
- Two Strikes and Monoclonal Antibodies Are Out for Early Parkinson's?
"The negative data have apparently not deterred the sponsor of PASADENA from commencing a phase 2b trial, although it does seem likely that the evidence in aggregate marks the end of the road for ...
- Meridian woman rides 8,000 miles for Parkinson’s Disease
Joni Pursell took her motorcycle across the country and back to honor those dealing with Parkinson’s disease. MERIDIAN, Idaho — Joni Pursell has been riding her motorcycle for many years now. She ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Bupa Counselling in Belfast
I am an experienced Clinical Psychologist working with young people and adults with a range of difficulties. I have held posts working with people with a range of mental health difficulties as ...
- Ambiguous relations in international and local politics aren’t new
whereas in the same year no travel permit was required for travel to Dublin. WA Miller, Belfast BT13 Ben Lowry: For some reason unionists would not turn against Boris Johnson ...
14 hours agoLast updated 14 hours ago Updated Monday to Friday only This morning will see plenty of sunny spells. In the afternoon patches of cloud will build in from the west for most. A chance ...